Cargando…

Major Adverse Cardiovascular Events (MACE) in COVID-19 Infection and the Role of Cardiac Biomarkers: A Systematic Literature Review

Detalles Bibliográficos
Autores principales:	Mahendran, S., Amarasekera, A., Li, C., Padhi, A., Vien, A., Malaty, M., Tan, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324094/ http://dx.doi.org/10.1016/j.hlc.2021.06.304

Ejemplares similares

MACE in the Race: A Canadian Perspective on Major Adverse Cardiac Events (MACE) During Running
por: Abrahim, Mohammed
Publicado: (2022)

Association of Race and Major Adverse Cardiac Events (MACE): The Atherosclerosis Risk in Communities (ARIC) Cohort
por: Franey, Ericha G, et al.
Publicado: (2020)

Current Progress of Studies of Coronary CT for Risk Prediction of Major Adverse Cardiovascular Event (MACE)
por: Zheng, Jianan, et al.
Publicado: (2021)

The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD Readmissions
por: Kallis, Constantinos, et al.
Publicado: (2023)

Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study
por: Farshidi, Hossein, et al.
Publicado: (2018)

A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19)
por: Huang, Dong, et al.
Publicado: (2022)

Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights
por: Marsal, Josep Ramon, et al.
Publicado: (2022)

Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
por: Chen, Dongqing, et al.
Publicado: (2023)

Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis
por: Sutanto, Andryanto, et al.
Publicado: (2021)

Association Between Troponin Elevation and Severity of COVID-19 Infection: A Systematic Review and Meta-Analysis
por: Mahendran, S., et al.
Publicado: (2022)

Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin
por: Sardu, Celestino, et al.
Publicado: (2019)

331 A Machine Learning-based Pharmacogenomic Association Study of Major Adverse Cardiovascular Events (MACEs) in Caribbean Hispanic Patients on Clopidogrel
por: Arroyo, Luis A. Rosario, et al.
Publicado: (2022)

4423 Impact of Gender on High On-Treatment Platelet Reactivity (HPR) and Major Adverse Cardiovascular Events (MACEs) in Caribbean Hispanic patients using Clopidogrel
por: Nunez Medina, Hector Jose, et al.
Publicado: (2020)

Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes
por: Xie, Gaoqiang, et al.
Publicado: (2017)

Retrospective Study of Appropriate Primary Prevention in Postmenopausal Women Presenting with a Major Adverse Cardiovascular Endpoint (MACE)
por: Cieri-Hutcherson, Nicole E., et al.
Publicado: (2022)

Risk prediction model for major adverse cardiovascular events (MACE) during hospitalization in patients with coronary heart disease based on myocardial energy metabolic substrate
por: Na, Li, et al.
Publicado: (2023)

Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study
por: Reyes, Luis Felipe, et al.
Publicado: (2023)

O054 What Measure of CPAP Treatment is most closely Associated with Reduced Risk of Future Major Cardiovascular Events (MACE)?
por: Reynor, A, et al.
Publicado: (2023)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Risk of a major adverse cardiovascular event (MACE) following first-ever hospitalisation for acute gout: a Western Australian population-level linked data study.
por: Lopez, Derrick, et al.
Publicado: (2022)

The association between 24-h blood pressure variability and major adverse cardiac events (MACE) in hospitalized patients with acute myocardial infarction: a retrospective cohort study
por: Harefa, et al.
Publicado: (2021)

Association between high sensitivity C-reactive protein (hs-CRP) levels and the risk of major adverse cardiovascular events (MACE) and/or microembolic signals after carotid angioplasty and stenting
por: Foroughinia, Farzaneh, et al.
Publicado: (2019)

Cardiac Biomarkers Predicting MACE in Patients Undergoing Noncardiac Surgery: A Meta-Analysis
por: Zhang, Li-Jun, et al.
Publicado: (2019)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

Rhinitis induced to mace
por: Sanchez Moreno, Gema Vanesa, et al.
Publicado: (2011)

Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events (MACE) and mortality in patients with heart disease and critically ill patients. Part I: Epicardial adipose tissue
por: Walpot, Jeroen, et al.
Publicado: (2023)

Comparison of cardiovascular biomarker expression in extracellular vesicles, plasma and carotid plaque for the prediction of MACE in CEA patients
por: Verwer, Maarten C., et al.
Publicado: (2023)

Effects of opium use on one-year major adverse cardiovascular events (MACE) in the patients with ST-segment elevation MI undergoing primary PCI: a propensity score matched - machine learning based study
por: Jenab, Yaser, et al.
Publicado: (2023)

Association of Major Adverse Cardiovascular Events in Patients With Stroke and Cardiac Wall Motion Abnormalities
por: Kamran, Saadat, et al.
Publicado: (2021)

Biomaker evaluation for major adverse cardiovascular event development in patients undergoing cardiac Surgery
por: Imperiali, Claudia E., et al.
Publicado: (2020)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Major adverse cardiovascular events in older emergency department patients presenting with non-cardiac medical complaints
por: Zelis, N., et al.
Publicado: (2022)

Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review
por: Birker, Sebastian, et al.
Publicado: (2022)

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis
por: Palazzo, A., et al.
Publicado: (2023)

Monocyte to High-Density Lipoprotein Ratio (MHR) as a predictor of mortality and Major Adverse Cardiovascular Events (MACE) among ST Elevation Myocardial Infarction (STEMI) patients undergoing primary percutaneous coronary intervention: a meta-analysis
por: Villanueva, Danielle Louis E., et al.
Publicado: (2020)

Necroptosis Drives Major Adverse Cardiovascular Events During Severe COVID-19
por: Wiscovitch-Russo, Rosana, et al.
Publicado: (2023)

Major adverse cardiovascular events are associated with necroptosis during severe COVID-19
por: Wiscovitch-Russo, Rosana, et al.
Publicado: (2023)

Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
por: Mal, Kheraj, et al.
Publicado: (2020)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_albc5hp7cpe0l5h1582978avqg